Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) ‐ outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients
Shuangtao Zhao(The University of Texas MD Anderson Cancer Center), Preetesh Jain(The University of Texas MD Anderson Cancer Center), Wendy Chen(The University of Texas MD Anderson Cancer Center), Keyur P. Patel(The University of Texas MD Anderson Cancer Center), Krystle Nomie(The University of Texas MD Anderson Cancer Center), Raphel Steiner(The University of Texas MD Anderson Cancer Center), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Lucy Navsaria(The University of Texas MD Anderson Cancer Center), Xingzhi Song(The University of Texas MD Anderson Cancer Center), Swaminathan P. Iyer(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Dapeng Hao(The University of Texas MD Anderson Cancer Center), Selvi Thirumurthi(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Guangchun Han(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), Yixin Yao(The University of Texas MD Anderson Cancer Center), Linghua Wang(The University of Texas MD Anderson Cancer Center), Chi Young Ok(The University of Texas MD Anderson Cancer Center), Guilin Tang(The University of Texas MD Anderson Cancer Center), Rashmi Kanagal‐Shamanna(The University of Texas MD Anderson Cancer Center), Omar Moghrabi(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Changying Jiang(Canada Research Chairs), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Christopher R. Flowers(The University of Texas MD Anderson Cancer Center), Holly A. Hill(National Center for Immunization and Respiratory Diseases), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Jianhua Zhang(XinHua Hospital), Michael Wang(St. Joseph Health System), Shaojun Zhang(The University of Texas MD Anderson Cancer Center), Guofan Xu(The University of Texas MD Anderson Cancer Center), Shaoying Li(Third Affiliated Hospital of Guangzhou Medical University), Leonard Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Jorge Moreno Aranda(The University of Texas MD Anderson Cancer Center), Maria Badillo(The University of Texas MD Anderson Cancer Center), Onyeka Oriabure(The University of Texas MD Anderson Cancer Center), C. Cameron Yin(Chinese Academy of Agricultural Sciences), Ranjit Nair(NewYork–Presbyterian Brooklyn Methodist Hospital), Francisco Vega(The University of Texas MD Anderson Cancer Center)
Cited by 84
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
2016 US lymphoid malignancy statistics by World Health Organization subtypes
|CA A Cancer Journal for Clinicians|2016|1.1k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k